Search

Your search keyword '"Dimou, Maria"' showing total 5 results
Start Over Author "Dimou, Maria" Journal british journal of haematology
5 results on '"Dimou, Maria"'

1. The effect of 5‐azacytidine treatment delays and dose reductions on the prognosis of patients with myelodysplastic syndrome: how to optimize treatment results and outcomes

Author

Diamantopoulos, Panagiotis T., primary, Symeonidis, Argiris, additional, Pappa, Vasiliki, additional, Kotsianidis, Ioannis, additional, Galanopoulos, Athanasios, additional, Pontikoglou, Charalampos, additional, Anagnostopoulos, Achilles, additional, Vassilopoulos, George, additional, Zikos, Panagiotis, additional, Hatzimichael, Eleftheria, additional, Papaioannou, Maria, additional, Megalakaki, Aekaterini, additional, Repousis, Panagiotis, additional, Kotsopoulou, Maria, additional, Dimou, Maria, additional, Solomou, Elena, additional, Dryllis, Georgios, additional, Tsokanas, Dimitrios, additional, Papoutselis, Menelaos‐Konstantinos, additional, Papageorgiou, Sotirios, additional, Kyrtshonis, Marie‐Christine, additional, Kourakli, Alexandra, additional, Papadaki, Helen, additional, Panayiotidis, Panayiotis, additional, and Viniou, Nora‐Athina, additional

Published
2020
Full Text
View/download PDF

2. Validation of the simplified International Prognostic Score3 in a Hellenic cohort of patients with advanced‐stage Hodgkin‐lymphoma

Author

Asimakopoulos, John V., primary, Angelopoulou, Maria K., additional, Arapaki, Maria‐Panagiota, additional, Kanellopoulos, Alexandros, additional, Dimou, Maria, additional, Giakoumis, Xanthoula, additional, Konstantinou, Eliana, additional, Belia, Marina, additional, Chatzidimitriou, Chrysovalantou, additional, Sachanas, Sotirios, additional, Iliakis, Theodoros, additional, Kyrtsonis, Marie‐Christine, additional, Siakantaris, Marina P., additional, Viniou, Nora‐Athina, additional, Variamis, Eleni, additional, Kontopidou, Flora N., additional, Pangalis, Gerassimos A., additional, Panayiotidis, Panayiotis, additional, Konstantopoulos, Kostas, additional, and Vassilakopoulos, Theodoros P., additional

Published
2020
Full Text
View/download PDF

3. Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma

Author

Kyrtsonis, Marie-Christine, Vassilakopoulos, Theodoros P., Kafasi, Nicoletta, Sachanas, Sotirios, Tzenou, Tatiana, Papadogiannis, Argiroula, Galanis, Zacharoula, Kalpadakis, Christina, Dimou, Maria, Kyriakou, Elias, Angelopoulou, Maria K., Dimopoulou, Maria N., Siakantaris, Marina P., Dimitriadou, Evangelia M., Kokoris, Styliani I., Panayiotidis, Panayiotis, and Pangalis, Gerassimos A.

Published
2007

4. Serial determination of FLT3 mutations in myelodysplastic syndrome patients at diagnosis, follow up or acute myeloid leukaemia transformation: incidence and their prognostic significance

Author

Georgiou, Georgios, Karali, Vasiliki, Zouvelou, Christina, Kyriakou, Elias, Dimou, Maria, Chrisochoou, Stamatis, Greka, Paraskevi, Dufexis, Dimitrios, Vervesou, Elisavet, Dimitriadou, Evaggelia, Efthymiou, Anna, Petrikkos, Loizos, Dima, Katerina, Lilakos, Konstantinos, and Panayiotidis, Panayiotis

Published
2006

5. The effect of 5‐azacytidine treatment delays and dose reductions on the prognosis of patients with myelodysplastic syndrome: how to optimize treatment results and outcomes.

Author

Diamantopoulos, Panagiotis T., Symeonidis, Argiris, Pappa, Vasiliki, Kotsianidis, Ioannis, Galanopoulos, Athanasios, Pontikoglou, Charalampos, Anagnostopoulos, Achilles, Vassilopoulos, George, Zikos, Panagiotis, Hatzimichael, Eleftheria, Papaioannou, Maria, Megalakaki, Aekaterini, Repousis, Panagiotis, Kotsopoulou, Maria, Dimou, Maria, Solomou, Elena, Dryllis, Georgios, Tsokanas, Dimitrios, Papoutselis, Menelaos‐Konstantinos, and Papageorgiou, Sotirios

Subjects
MYELODYSPLASTIC syndromes, TREATMENT delay (Medicine), PROGNOSIS, ACUTE myeloid leukemia, TREATMENT effectiveness
Abstract

Summary: The regimen of 5‐azacytidine for patients with myelodysplastic syndrome (MDS) has remained unchanged since its first approval. Although several modifications have since been made and delays and dose reductions are common especially during the first treatment cycles, there are minimal data on the prognostic effect of these modifications. In this study, based on data from 897 patients with MDS treated with 5‐azacytidine recorded in a national registry, the effect of treatment delays and dose reductions on response, transformation to acute myeloid leukaemia, and survival (after 5‐azacytidine initiation, OST) were analysed. Delays during the first two cycles were noted in 150 patients (16·7%) and were found to adversely affect OST independently of the International Prognostic Scoring System score [hazard ratio (HR), 1·368; P = 0·033] or pre‐existing neutropenia (HR, 1·42; P = 0·015). In patients achieving a response, delays before response achievement were correlated with its type (complete remission, 2·8 days/cycle; partial remission, 3·3 days/cycle; haematologic improvement, 5·6 days/cycle; P = 0·041), while delays after response achievement did not have any effect on retention of response or survival. Dose reductions were found to have no prognostic impact. Based on our results, treatment delays especially during the first cycles should be avoided, even in neutropenic patients. This strict strategy may be loosened after achieving a favourable response. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results